Examples of 'renal or hepatic impairment' in a sentence
Meaning of "renal or hepatic impairment"
Renal or hepatic impairment refers to the condition or state of having functional abnormalities or damages in the kidneys (renal impairment) or the liver (hepatic impairment). These impairments can result from various factors, such as diseases, infections, toxins, or medications, and may affect the respective organ's ability to perform its functions properly
How to use "renal or hepatic impairment" in a sentence
Basic
Advanced
renal or hepatic impairment
Renal or hepatic impairment and liver fibrosis.
Dosing adjustment for renal or hepatic impairment.
Renal or hepatic impairment may reduce insulin requirement.
Colchicine in patients with renal or hepatic impairment.
Patients with renal or hepatic impairment should be monitored closely.
Protein binding is not affected by renal or hepatic impairment.
Renal or hepatic impairment.
Subjects with renal or hepatic impairment.
No pharmacokinetic data are available in patients with renal or hepatic impairment.
Patients with renal or hepatic impairment.
No dose adjustment is required for patients with renal or hepatic impairment.
This effect is aggravated by renal or hepatic impairment and by prolonged duration of treatment.
No studies have been conducted in patients with renal or hepatic impairment.
Uremia and renal or hepatic impairment may cause a breath with smell of urine.
Au expected to be affected by renal or hepatic impairment.
See also
Patients with severe renal or hepatic impairment should be carefully monitored for adverse effects.
Tell your doctor if you have renal or hepatic impairment.
Renal or hepatic impairment Taltz has not been studied in these patient populations.
Tecfidera has not been studied in patients with renal or hepatic impairment.
Patients with renal or hepatic impairment should not be given colchicine with PREZISTA.
The clearance of mirtazapine may be decreased as a result of renal or hepatic impairment.
Renal or hepatic impairment may reduce the patient 's insulin requirements.
Mirvaso has not been studied in patients with renal or hepatic impairment.
Patients with renal or hepatic impairment should not be given colchicine with nelfinavir see section 4.4.
Axumin has not been studied in patients with renal or hepatic impairment.
For patients with renal or hepatic impairment colchicine with boosted PREZISTA is contraindicated see section 4.3.
Pharmacokinetics in paediatric patients with renal or hepatic impairment have not been studied.
Severe renal or hepatic impairment creatinine clearance of less than 30 mL / min and / or Child-Pugh Class C.
The pharmacokinetics in patients with renal or hepatic impairment has not been characterised.
No studies were conducted to evaluate daclizumab pharmacokinetics in patients with renal or hepatic impairment.
The pharmacokinetics in patients with renal or hepatic impairment have not been characterised.
Careful treatment is required in patients with known or suspected renal or hepatic impairment.
Dose adjustments in renal or hepatic impairment are not necessary See Section 4.4 and Section 5.2.
Formal studies have not been performed in patients with renal or hepatic impairment.
Special population, Patients with clinically significant renal or hepatic impairment may experience more adverse events.
Studies have not been conducted to examine the effects of renal or hepatic impairment.
The pharmacokinetics of nusinersen in patients with renal or hepatic impairment has not been studied.
Trifluoperazine should be used with caution in patients suffering from renal or hepatic impairment.
The pharmacokinetics of florbetaben ( 18F ) in patients with renal or hepatic impairment has not been characterised.
Plasma protein binding is not meaningfully altered in patients with renal or hepatic impairment.
The pharmacokinetics of florbetapir ( 18F ) in patients with renal or hepatic impairment have not been characterised.
No dose adjustments are necessary for the elderly or patients with renal or hepatic impairment.
Special populations Patients with renal or hepatic impairment.
Pharmacokinetic studies have not been performed in patients with renal or hepatic impairment.
Renal / hepatic impairment The pharmacokinetics in patients with renal or hepatic impairment have not been characterised.
Colchicine CYP3A4 inhibition by ritonavir Contraindicated in patients with renal or hepatic impairment.
No dose adjustment is required in patients with renal or hepatic impairment see section 5.2.
Idelalisib should not be co-administered with colchicine to patients with renal or hepatic impairment.
The pharmacokinetics of flutemetamol ( 18F ) in patients with renal or hepatic impairment has not been characterised.
Specific studies of golimumab have not been conducted in patients with renal or hepatic impairment.
You'll also be interested in:
Examples of using Hepatic
Show more
Progressive renal or hepatic end organ dysfunction
Hepatic toxicity has been associated with acetaminophen
Monitoring of the hepatic function is also recommended
Examples of using Renal
Show more
He had some renal issues last year
Renal perfusion and circulation time are reduced
The kid had a renal artery thrombosis
Examples of using Impairment
Show more
An impairment test is realized during each closing
You have a neurological impairment called somatoparaphrenia
Impairment testing is done at the individual investment level
